scispace - formally typeset
J

Jisnuson Svasti

Researcher at Chulabhorn Research Institute

Publications -  276
Citations -  5498

Jisnuson Svasti is an academic researcher from Chulabhorn Research Institute. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 40, co-authored 255 publications receiving 4719 citations. Previous affiliations of Jisnuson Svasti include University of Mainz & Victoria University of Wellington.

Papers
More filters
Journal ArticleDOI

Antiviral isoflavonoid sulfate and steroidal glycosides from the fruits of Solanum torvum.

TL;DR: Torvanol A (1), torvoside H (3) and compound 5 exhibited antiviral activity (herpes simplex virus type 1) with IC(50) values of 9.6, 23.2 and 17.4 microg/ml, respectively.
Journal ArticleDOI

Vanillin suppresses in vitro invasion and in vivo metastasis of mouse breast cancer cells

TL;DR: The findings suggest that vanillin has anti-metastatic potential by decreasing invasiveness of cancer cells and may be of value in the development of anti- Metastatic drugs for cancer treatment.
Journal ArticleDOI

Vanillin suppresses metastatic potential of human cancer cells through PI3K inhibition and decreases angiogenesis in vivo.

TL;DR: Vanillin and apocynin could inhibit the enzymatic activity of phosphoinositide 3-kinase (PI3K), suggesting that inhibition of PI3K activity was a mechanism underlying the inhibitory effect on cancer cell migration, and the presence of an aldehyde or ketone group in the vanillin structure was important for this inhibition.
Journal ArticleDOI

Mucoadhesive curcumin nanospheres: Biological activity, adhesion to stomach mucosa and release of curcumin into the circulation

TL;DR: Two monopolymeric carrier and a dipolymeric carrier made from a blend of methylcellulose and EC yielded the highest reported curcumin loading and showed an in vitro free radical scavenging activity and a dose-dependent in vitro cytotoxic effect towards MCF-7 human breast adenocarcinoma and HepG2 hepatoblastoma cells in tissue culture.
Journal ArticleDOI

Lupeol and stigmasterol suppress tumor angiogenesis and inhibit cholangiocarcinoma growth in mice via downregulation of tumor necrosis factor-α.

TL;DR: The findings indicate that lupeol and stigmasterol effectively target tumor endothelial cells and suppress CCA tumor growth by their anti-inflammatory activities and are attractive candidates for anti-cancer treatment of CCA tumors.